Transdermal Platform Bypasses 500-Dalton Rule, Aims at Tumor Acidity

Only about 30 drugs have ever earned transdermal approval, and they share a narrow profile: small, lipophilic, potent. Dyve Biosciences says its platform breaks that mold, with human data on more than a dozen molecules and absorption that peaks within roughly 15 minutes.

The company's lead oncology candidate, DV800, now heads toward human cancer trials in partnership with Moffitt Cancer Center. The first targets will be superficial and cutaneous tumors, including melanoma and squamous cell carcinoma, before moving into head and neck cancers and triple-negative breast cancer.

How does the skin barrier get opened?

Dr. Ryan Beal, co-founder and CEO, describes the skin's outer layer as a brick wall. The cells are bricks. The lipids between them are mortar. Junctional proteins deeper down act like rebar.

His company's topical formulation fluidizes that lipid mortar and transiently opens the deeper junctions. "We open a window and then shut it," Beal said in an interview with Inside Precision Medicine.

The result is a delivery range that ignores Lipinski's rules. Conventional thinking caps transdermal molecules at roughly 500 daltons. Dyve reports a solid dataset extending into single-digit kilodaltons, and partners are now testing triple-digit-kilodalton proteins.

"It's almost as if our topical formulation has billions of little microneedles in it, but there's nothing physical or mechanical about it," Beal said. "It's biochemistry that's opening those junctions."

Absorption runs close to the speed of a subcutaneous injection. Molecules reach circulation in low-single-digit minutes to about 15 minutes. The two gates in the skin can also be modulated separately, trapping a drug in the dermis for local effect or allowing slow systemic release over hours. In effect, the platform lets developers shape the pharmacokinetic curve.

Beal frames the technology as a rival to injections and oral dosing, not to nicotine and scopolamine patches. "When there's an existing path to delivering something topically or transdermally using established technology, we're not interested," he said.

Why sodium bicarbonate for cancer?

Researchers have known tumors are acidic for over a century, dating back to Otto Warburg's Nobel-winning work. For decades, acidity looked like a mere byproduct of glycolysis. The past 20 years reframed it as causal, driving progression, suppressing immune response, and blunting both immunotherapy and chemotherapy uptake.

Sodium bicarbonate offered one logical neutralizer. Oral dosing hit hard limits. Beal said bicarbonate checked every box his team screens for: it needs a large sustained dose, it is poorly soluble, and existing transdermal tech cannot carry it.

The clinical strategy starts where the biology is easiest to see. "If I have melanoma on my skin, I'm going to treat it. If I have squamous cell carcinoma, I'm going to treat it," Beal said. Superficial tumors also permit paired biopsies and biomarker analysis that deep pancreatic, liver, or bladder tumors make difficult, even where preclinical data are strong.

Aggressiveness matters too. More aggressive cancers tend to show a more acidic phenotype, and that filter shapes which tumor types Dyve pursues.

Could acidity neutralization boost immunotherapy?

Animal studies already suggest DV800 works as a monotherapy, and combination studies there have been extensive. Human combination trials come later.

Beal's framing shifts the usual "turning a tumor hot" language. He prefers turning the immune system back on, calling tumor acidity an upstream checkpoint sitting above all the downstream pathways researchers currently target.

"Every other therapy is essentially swimming against the current, with acidity being that current," he said. Neutralize it, he argued, and antibody-drug conjugates, bispecifics, and other immunotherapies could lift response rates across the field.

He concedes the point plainly: that potential still needs clinical demonstration.

Beal brings an unusual resume to the effort, with roots in skincare and endurance sports before oncology, and his own history as a cancer patient shaped his sense of urgency. The Moffitt collaboration now carries that urgency into first-in-human work, with superficial tumors as the proving ground.